Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their...
DNA: Coding Vs. NON-Coding The completion of the Human Genome Project in 2003 revealed a big surprise: up to 98% of the DNA making up the human genome does not code for proteins! The notion that parts of the genome were non-coding had been circulating for several...
Last week, the FDA’s Oncologic Drugs Advisory Committee unanimously recommended Novartis’ biosimilar version of Amgen’s megahit Neupogen (filgrastim), effectively paving the way for the first US biosimilar approval in the near future. Filgrastim is a...
About Biotech Primer
From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.
